Patents by Inventor John Ridden
John Ridden has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11484512Abstract: The present invention relates to a composition for use in the treatment of onychomycosis and/or tinea pedis, the composition comprising a polymer capable of forming nanoparticles and terbinafine, or derivative or salt thereof, wherein the nanoparticles are formed with and/or in the presence of terbinafine, or derivative or salt thereof and wherein the composition is administered topically to provide a daily dose to an infected area in the range of about 5 ?g to about 50 ?g of terbinafine. The invention also relates to a combination of the composition and a liquid dispensing device for dispensing a pre-defined quantity of the composition to a user's toes and/or inter-digital spaces and/or front of the foot.Type: GrantFiled: June 28, 2018Date of Patent: November 1, 2022Assignee: Blueberry Therapeutics LimitedInventors: John Ridden, Christine Caroline Ridden, David Cook, Julie Cook
-
Publication number: 20220133640Abstract: The present invention relates nanoparticles formed of a polymer and an antifungal agent, wherein the polymer is selected from the group consisting of linear or branched or cyclic polymonoguanide/polyguanidine, polybiguanide, analogues or derivatives thereof, or mixtures thereof. The nanoparticles are particularly suited for the treatment of fungal nail or skin infections.Type: ApplicationFiled: October 27, 2021Publication date: May 5, 2022Inventors: John RIDDEN, Michael DAVIES, Liam GOOD
-
Patent number: 11185511Abstract: The present invention relates to a topical composition (and methods of producing the such compositions) for the treatment of a fungal infection comprising a polymer capable of forming nanoparticles and an antifungal agent. The invention also relates to novel uses of polyhexamethylene biguanide.Type: GrantFiled: September 25, 2014Date of Patent: November 30, 2021Assignee: BLUEBERRY THERAPEUTICS LIMITEDInventors: John Ridden, Michael Davies, Liam Good
-
Publication number: 20210275506Abstract: The present invention relates to compositions for use in the treatment of a dermatological condition, comprising a polymer capable of forming nanoparticles an anti-inflammatory and/or analgesic agent. The composition is particularly suited to the treatment of acne and/or atopic dermatitis. The invention also relates to novel uses of polyhexamethylene biguanide.Type: ApplicationFiled: July 3, 2019Publication date: September 9, 2021Inventors: Christine Ridden, John Ridden, David Cook
-
Publication number: 20210259981Abstract: The present invention relates to compositions for use in the treatment or management of inflammation and/or pain, comprising a polymer capable of forming nanoparticles an anti-inflammatory and/or analgesic agent. The invention also relates to novel uses of polyhexamethylene biguanide.Type: ApplicationFiled: July 3, 2019Publication date: August 26, 2021Inventors: Christine Ridden, John Ridden, David Cook
-
Publication number: 20200206160Abstract: The present invention relates to a composition for use in the treatment of a fungal infection comprising a polymer capable of forming nanoparticles and terbinafine, or derivative or salt thereof, wherein the nanoparticles are formed with and/or in the presence of terbinafine, or derivative or salt thereof, and where the composition comprises: a) a ratio of terbinafine, or derivative or salt thereof, to polymer in the range of about 1:2 to 1:4; and b) up to about 30% (v/v) alcohol. The composition is particularly suited as a topical treatment for fungal nail or skin infections. The invention also relates to methods of producing such compositions and combinations which can be used to produce said same.Type: ApplicationFiled: March 24, 2017Publication date: July 2, 2020Inventors: John Ridden, Christine Caroline Ridden, David Cook
-
Publication number: 20200155482Abstract: The present invention relates to a composition for use in the treatment of onychomycosis and/or tinea pedis, the composition comprising a polymer capable of forming nanoparticles and terbinafine, or derivative or salt thereof, wherein the nanoparticles are formed with and/or in the presence of terbinafine, or derivative or salt thereof and wherein the composition is administered topically to provide a daily dose to an infected area in the range of about 5 ?g to about 50 ?g of terbinafine. The invention also relates to a combination of the composition and a liquid dispensing device for dispensing a pre-defined quantity of the composition to a user's toes and/or inter-digital spaces and/or front of the foot.Type: ApplicationFiled: June 28, 2018Publication date: May 21, 2020Inventors: John Ridden, Christine Caroline Ridden, David Cook, Julie Cook
-
Patent number: 10517835Abstract: The present invention relates to a composition comprising nanoparticles formed of a polymer and terbinafine, wherein the nanoparticles comprise particles in the range of 0.5 to 5 nm and/or in the range of 150 to 250 nm. Such compositions are particularly suited, but not limited, to the treatment of fungal nail infections.Type: GrantFiled: July 6, 2016Date of Patent: December 31, 2019Assignee: Bueberry Therapeutics LimitedInventors: John Ridden, Christine Caroline Ridden, David Cook
-
Patent number: 10293024Abstract: A compound comprising the amino acid sequence HKSRALLIFQKIMWLRRQ (SEQ ID No: 1) or comprising a part of said amino acid sequence of 7 or more amino acids, or comprising a variant of said amino acid sequence or said part thereof in which from 1 to 5 amino acids have been altered, wherein the compound binds to MAP kinase p38?. The compounds are useful in binding to and inhibiting MAP kinase p38?, and are useful as research tools, in drug discovery, medicine, particularly for treating inflammatory conditions.Type: GrantFiled: August 15, 2014Date of Patent: May 21, 2019Assignee: Blueberry Therapeutics LimitedInventor: John Ridden
-
Publication number: 20180193281Abstract: The present invention relates to a composition comprising nanoparticles formed of a polymer and terbinafine, wherein the nanoparticles comprise particles in the range of 0.5 to 5 nm and/or in the range of 150 to 250 nm. Such compositions are particularly suited, but not limited, to the treatment of fungal nail infections.Type: ApplicationFiled: July 6, 2016Publication date: July 12, 2018Inventors: John Ridden, Christine Caroline Ridden, David Cook
-
Publication number: 20160206567Abstract: The present invention relates to a topical composition (and methods of producing the such compositions) for the treatment of a fungal infection comprising a polymer capable of forming nanoparticles and an antifungal agent. The invention also relates to novel uses of polyhexamethylene biguanide.Type: ApplicationFiled: September 25, 2014Publication date: July 21, 2016Inventors: John RIDDEN, Michael DAVIES, Liam GOOD
-
Publication number: 20160193281Abstract: A compound comprising the amino acid sequence HKSRALLIFQKIMWLRRQ (SEQ ID No: 1) or comprising a part of said amino acid sequence of 7 or more amino acids, or comprising a variant of said amino acid sequence or said part thereof in which from 1 to 5 amino acids have been altered, wherein the compound binds to MAP kinase p38?. The compounds are useful in binding to and inhibiting MAP kinase p38?, and are useful as research tools, in drug discovery, medicine, particularly for treating inflammatory conditions.Type: ApplicationFiled: August 15, 2014Publication date: July 7, 2016Inventor: John Ridden
-
Publication number: 20160089393Abstract: The present invention provides compositions and methods for sensitizing a bacterium to an antibacterial the method comprising the step of exposing the bacterium, in the presence of an entry-promoting agent, to an agent that inhibits antibacterial resistance. Methods for killing an antibacterial-resistant bacterium comprising the step of exposing the bacterium, in the presence of an entry-promoting agent, to an agent that inhibits antibacterial resistance and exposing the bacterium to an antibacterial are also provided. The methods may also include the step of identifying the bacterium and the antibacterial resistance profile of the bacterium and tailoring the methods accordingly. Exemplary entry promoting agents provided are polyhexamethylene biguanide (PHMB) and polyhexamethyleneguanide (PHMG). Exemplary agents that inhibit antibacterial resistance are agents that bindto and inhibit antibacterial-resistance determinants such as beta-lactamases, PBP2a, NDM-1 and Vim2.Type: ApplicationFiled: April 17, 2014Publication date: March 31, 2016Inventors: John Ridden, Liam Good
-
Publication number: 20050106638Abstract: The present invention relates to an isolated target sequence. The target sequence is a splice variant of PDE5 called a PDE5a1, a component of which is presented as SEQ ID No 1. The identified target sequence of the present invention may be used to as a target to identify agents (such as modulators) useful in the prevention and/or treatment of a disease associated with scarring and/or fibrosis or to selectively identify smooth muscle cells and myofibroblasts and myoepithelial cells in samples of normal and diseased tissue from individuals.Type: ApplicationFiled: August 30, 2004Publication date: May 19, 2005Applicant: Pfizer Inc.Inventors: Dinah Parums, Stephen Phillips, John Ridden
-
Patent number: 6794192Abstract: The present invention relates to an isolated target sequence. The target sequence is a splice variant of PDE5 called a PDE5a1, a component of which is presented as SEQ ID No 1. The identified target sequence of the present invention may be used to as a target to identify agents (such as modulators) useful in the prevention and/or treatment of a disease associated with scarring and/or fibrosis or to selectively identify smooth muscle cells and myofibroblasts and myoepithelial cells in samples of normal and diseased tissue from individuals.Type: GrantFiled: June 28, 2001Date of Patent: September 21, 2004Assignee: Pfizer Inc.Inventors: Dinah Parums, Stephen Charles Phillips, John Ridden
-
Publication number: 20030040041Abstract: The present invention relates to an isolated target sequence. The target sequence is a splice variant of PDE5 called a PDE5a1, a component of which is presented as SEQ ID No 1. The identified target sequence of the present invention may be used to as a target to identify agents (such as modulators) useful in the prevention and/or treatment of a disease associated with scarring and/or fibrosis or to selectively identify smooth muscle cells and myofibroblasts and myoepithelial cells in samples of normal and diseased tissue from individuals.Type: ApplicationFiled: June 28, 2001Publication date: February 27, 2003Inventors: Dinah Parums, Stephen Charles Phillips, John Ridden